Ferric Maltol

Brand names: Accrufer ยท Active ingredient: Ferric Maltol

In short: ACCRUFER is indicated for the treatment of iron deficiency in adult and pediatric patients 10 years of age and older.

Forms & strengthsCapsules: ACCRUFER contains 30 mg iron, as ferric maltol, in red capsules printed with โ€œ30โ€.
LabelShield TX (UK) Ltd
Label updatedJan 05, 2026

What is Ferric Maltol used for?

ACCRUFER is indicated for the treatment of iron deficiency in adult and pediatric patients 10 years of age and older.

Ferric Maltol dosage

Adults and Children Aged 10 Years and Aboveโ€‹

The recommended dosage of ACCRUFER is 30 mg orally twice daily, on an empty stomach 1 hour before or 2 hours after meals.

Swallow capsules whole. Do not open, break, or chew capsules.

Treatment duration will depend on the severity of iron deficiency but generally at least 12 weeks of treatment is required. The treatment should be continued as long as necessary until ferritin levels are within the normal range.

How to take Ferric Maltol โ€” instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Administration

Inform patients to take ACCRUFER as directed on an empty stomach 1 hour before or 2 hours after meals. Instruct patients on concomitant medications that should be dosed apart from ACCRUFER

.

Advise patients to swallow the capsules whole and not to open, break, or chew capsules.

Adverse Reactions

Advise patients that ACCRUFER may cause, flatulence, diarrhea, constipation, discolored feces, abdominal pain, nausea, vomiting or abdominal bloating or discomfort. Advise patients to report severe or persistent gastrointestinal symptoms or any allergic reactions to their physician

.

Increased Risk of IBD Flare

Advise patients that they should not use ACCRUFER if they are experiencing an IBD flare

.

Iron Overload and Risk of Accidental Overdose in Children

Inform patients to keep this product out of reach of children as accidental overdose of iron products is a leading cause of fatal poisonings in children. In case of accidental overdose, advise them to call a doctor or poison control center immediately

.

Distributed by Shield Therapeutics Inc, 7-57 Wells Avenue Newton, MA, 02459

Warnings & precautions

Do not take this medicine if: ACCRUFER is contraindicated in patients with a history of:

Hypersensitivity to the active substance or to any of the excipients

. Reactions could include shock, clinically significant hypotension, loss of consciousness, and/or collapse.

Hemochromatosis and other iron overload syndromes

. Use may result in iron overdose

.

Receiving repeated blood transfusions. Use may result in iron overload

.

Avoid use of ACCRUFER in patients with an active inflammatory bowel disease (IBD) flare, as there is potential risk of increased inflammation in the gastrointestinal tract.

Excessive therapy with iron products can lead to excess storage of iron with the possibility of iatrogenic hemosiderosis. Do not administer ACCRUFER to patients with evidence of iron overload or patients receiving intravenous iron

. Assess iron parameters prior to initiating ACCRUFER and monitor iron parameters while on therapy

.

Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately.

Ferric Maltol side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Increased Risk of Inflammatory Bowel Disease Flare

Iron Overload

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data described below reflect exposure to ACCRUFER in 175 adult patients in the placebo-controlled phase of three randomized studies conducted in patients with anemia and quiescent inflammatory bowel disease (IBD) (Studies AEGIS 1 & 2) or non-dialysis dependent chronic kidney disease (CKD) (AEGIS 3). The pooled patient population had a mean age of 58 years, 67.4% were female (n=118), and 81.7% (n=143) were Caucasian.

Table 1 presents all adverse reactions occurring in the placebo-controlled period of the pooled randomized studies

occurring at a rate of > 1% in the treated group, and for which the rate for ACCRUFER exceeds the rate for placebo. โ€ฆ

Drug interactions

Oral Medications

There are no empirical data on avoiding drug interactions between ACCRUFER and concomitant oral medications. Concomitant use of some drugs may reduce the bioavailability of iron after administration of ACCRUFER. Separate the administration of ACCRUFER from these drugs. The duration of separation may depend on the absorption characteristics of the medication concomitantly administered, such as time to peak concentration or whether the drug is an immediate or extended release product. Monitor clinical response to ACCRUFER.

Dimercaprol

Concomitant use of iron products with dimercaprol may increase the risk of nephrotoxicity. Avoid concomitant use of ACCRUFER with dimercaprol.

Oral Medications

Concomitant use of ACCRUFER may decrease the bioavailability of some drugs, including mycophenolate, ethinyl estradiol, ciprofloxacin and doxycycline

. For oral drugs where reductions in bioavailability may cause clinically significant effects on its safety or efficacy, separate the administration of ACCRUFER by at least 4 hours. Monitor clinical responses to concomitant drugs as appropriate.

About this medicine

ACCRUFER (ferric maltol) capsules, an iron replacement product for oral administration, contain 30 mg iron and 201.5 mg maltol. Ferric maltol contains iron in a stable ferric state as a complex with a trimaltol ligand. Ferric maltol is 3-hydroxy-2-methyl-4H-pyrane-4-one iron (III) complex (3:1) and has the molecular formula (C

6H

5O

3)

3Fe and a molecular mass of 431.2.

Each red capsule, printed with โ€œ30โ€, contains colloidal anhydrous silica, crospovidone (Type A), lactose monohydrate, magnesium stearate and sodium lauryl sulfate as inactive ingredients. In addition, the capsule shell contains FD&C Blue No. 1, FD&C Red No. 40, FD&C Yellow No.6, hypromellose and titanium dioxide. The ink used for printing the marking contains Shellac, ammonium hydroxide, ethanol, iron oxide black and propylene glycol.

How it works: ACCRUFER delivers iron for uptake across the intestinal wall and transfer to transferrin and ferritin. ACCRUFER has been shown to increase serum iron parameters, including ferritin and transferrin saturation (TSAT) in adults and pediatric patients 10 years and older. โ€ฆ

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label โ€” it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 367ac157-2d25-4f34-99ce-b126e0f03851. Read the full official label on DailyMed.